Peptide receptor radionuclide therapy of neuroendocrine neoplasms: current advance and future direction
10.3760/cma.j.cn321828-20230822-00030
- VernacularTitle:神经内分泌肿瘤的肽受体放射性核素治疗：目前进展和未来方向
- Author:
Hao WANG
1
;
Wei ZHANG
;
Zhaohui ZHU
Author Information
1. 四川省医学科学院·四川省人民医院(电子科技大学附属医院)核医学科，成都 610072
- Keywords:
Neuroendocrine tumors;
Receptors, peptide;
Organometallic compounds;
Trends
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2023;43(11):695-700
- CountryChina
- Language:Chinese
-
Abstract:
Neuroendocrine neoplasms (NEN) are heterogeneous tumors originating from neuroendocrine cells, characterized by over expression of somatostatin receptors (SSTR) on the cell surface, with an increasing incidence year by year. In recent years, the peptide receptor radionuclide therapy (PRRT), using radionuclide-labeled somatostatin analogues to combine with SSTR, is developing rapidly and has played an important role in the treatment of NEN. PRRT is considered as a systemic, effective and safe treatment option for metastatic or unresectable SSTR-positive NEN. This article summarizes the method, effectiveness, toxic effect, and treatment measures of PRRT for NEN patients. The future development of PRRT is also discussed in combination with the important advances in recent years.
